Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098397 | 0.91 | ACHE (0.44) | ACHETDP1GAAALDH1A1CA2 | |
| SCHEMBL2438805 | 0.86 | — | — | |
| SCHEMBL148576 | 0.86 | — | — | |
| SCHEMBL10098407 | 0.84 | SRD5A2 (0.47) | ACHETDP1ALDH1A1TSHRCYP2A6 | |
| SCHEMBL22182454 | 0.84 | TEAD4 (0.54) | ACHETDP1GAAALDH1A1CA2 | |
| SCHEMBL20077077 | 0.84 | HPGD (0.56) | ACHETDP1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL8385547 | 0.80 | ACHE (0.53) | ACHETDP1GAAALDH1A1CA2 | |
| SCHEMBL1049035 | 0.80 | ACHE (0.53) | ACHETDP1GAAALDH1A1CA2 | |
| Toluene SCHEMBL28861237 | 0.79 | ACHE (0.61) | ACHETDP1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL2579397 | 0.76 | ALDH1A1 (0.32) | TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12230497-B2 | Methods for forming a topographically selective silicon oxide film by a cyclical plasma-enhanced deposition process | ASM IP HOLDING B.V. (NL) | 2025-02-18 | — | — | US | disclosed |
| US-12227529-B2 | Method of preparing silanols with selective cytochrome P450 variants and related compounds and compositions | DOW SILICONES CORPORATION (US) | 2025-02-18 | — | — | US | disclosed |
| CN-118852230-A | Preparation method of polysubstituted hydrosilane compound | 中国科学院兰州化学物理研究所 | 2024-10-29 | — | — | CN | disclosed |
| CN-118027090-A | Method for generating silanol by oxidizing silane | 吉林大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-112593212-B | Method for forming topologically selective silicon oxide film by cyclic plasma enhanced deposition process | ASM IP私人控股有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4234643-A2 | ANTIFOULING COMPOSITION | Jotun A/S (NO) | 2023-08-30 | — | — | EP | disclosed |
| US-20230143580-A1 | METHODS FOR FORMING A TOPOGRAPHICALLY SELECTIVE SILICON OXIDE FILM BY A CYCLICAL PLASMA-ENHANCED DEPOSITION PROCESS | ASM IP HOLDING B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230102728-A1 | METHOD OF PREPARING SILANOLS WITH SELECTIVE CYTOCHROME P450 VARIANTS AND RELATED COMPOUNDS AND COMPOSITIONS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-03-30 | — | — | US | disclosed |
| US-11610774-B2 | Methods for forming a topographically selective silicon oxide film by a cyclical plasma-enhanced deposition process | ASM IP HOLDING B.V. (NL) | 2023-03-21 | — | — | US | disclosed |
| EP-4107162-A1 | METHOD OF PREPARING SILANOLS WITH SELECTIVE CYTOCHROME P450 VARIANTS AND RELATED COMPOUNDS AND COMPOSITIONS | Dow Silicones Corporation (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-0770084-A1 | SILYLMETHYL-ANILINE DERIVATIVES, METHODS OF PREPARATION AND USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1997-05-02 | — | — | EP | disclosed |
| US-5599957-A | OPTICALLY ACTIVE EPOXY COMPOUNDS FROM OLEFINS USING AN OPTICALLY ACTIVE MANGANESE COMPLEX HAVING NAPHTHYL GROUPS; CHEMICAL INTERMEDIATES OF DRUGS INCLUDING BENZOPYRANS; HYPOTENSIVE AGENTS; ASTHMA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1997-02-04 | — | — | US | disclosed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | disclosed |
| WO-1996001830-A1 | SILYLMETHYL-ANILINE DERIVATIVES, METHODS OF PREPARATION AND USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1996-01-25 | — | — | WO | disclosed |
| EP-0680484-A1 | OPTICALLY ACTIVE $g(b)-AMINOALKOXYBORANE COMPLEX | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1995-11-08 | — | — | EP | disclosed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | disclosed |
| EP-0669339-A1 | Asymmetric epoxidation process using optically active manganese complexes | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1995-08-30 | — | — | EP | disclosed |
| US-5420314-A | Enantiomorph manganese complex for oxidation | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| WO-1994017079-A1 | OPTICALLY ACTIVE β-AMINOALKOXYBORANE COMPLEX | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1994-08-04 | — | — | WO | disclosed |
| US-4474976-A | ARYLATION | GENERAL ELECTRIC COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102728-A1 | METHOD OF PREPARING SILANOLS WITH SELECTIVE CYTOCHROME P450 VARIANTS AND RELATED COMPOUNDS AND COMPOSITIONS | CYP2E1, POR, CYP3A43 | ACHE 2878/4885TDP1 2684/4885GAA 888/4885 |
| US-12227529-B2 | Method of preparing silanols with selective cytochrome P450 variants and related compounds and compositions | CYP2E1, POR, CYP3A43 | ACHE 2878/4885TDP1 2684/4885GAA 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.